FiO2 Delivered With Neonatal bCPAP

Delivered and Assessed FiO2 in Neonates With Respiratory Distress and Treated With Bubble-CPAP at a Neonatal Intensive Care Unit in Hanoi, Vietnam

Continuous positive airway pressure (CPAP) is the mainstay of treatment recommended for preterm infants with respiratory distress syndrome in all resource contexts. Many of the available bubble CPAP machines in low- and middle-income contexts mix flows of air and oxygen. These are adjusted by two separate rotameters (flowmeters) and estimate FiO2 delivery. Medical decisions regarding interventions to sick neonates such as need for intubation or surfactant administration are in large part dependant on a reliable estimation of FiO2-delivery. The aim of this study is to evaluate the accuracy of FiO2 delivered by bubble-CPAP machines with separate oxygen and air rotameters in patients at a neonatal intensive care unit (NICU) in Hanoi.

Study Overview

• Status: Completed
• Conditions: Infant, Newborn, Diseases; Infant, Premature, Diseases; Respiratory Distress Syndrome (RDS)

Detailed Description

This is a cross-sectional observational study. The patient population will be a convenience sample with patients recruited when investigators are available, and the measurement is possible without interrupting planned care. There is no intervention apart from measurements of FiO2 in the breathing circuit and parents will be given the opportunity to decline participation. The study aims to include FiO2 measurements from bCPAP machines in use where the infants have stable spontaneous breathing and not expected to need urgent interventions. The main outcomes of the study are FiO2 displayed by the analyzer (chemical sensor), FiO2 recorded compared to FiO2 assessed from the rotameter flow using the conversion table. The clinicians estimating the rotameter flows are blinded to the delivered FiO2.

There are 22 bubble CPAP machines in the NICU. We aim to collect four or five measurements on each machine at a range of FiO2-levels generating a total of approximately 100 measurements. Differences in FiO2 of 0.04 would be considered clinically relevant, since it might have implication for decision of surfactant treatment or intubation. FiO2 accuracy will be investigated by comparing paired samples from visual assessed FiO2 and measured FiO2 (electrochemical sensor) by appropriate statistical tests. Variation between and within the two types of CPAP machines will be described. Analysis will also describe accuracy at different FiO2 levels and variance of accuracy between clinicians' bedside estimates.

The main application for ethical approval of the study will be to the Ethical Review Board at Phu San Hanoi Hospital. Analysis and data will be handled by researchers affiliated with Karolinska Institutet, and a second application will be filed at the Swedish Ethical Review Authority.

The risk for an infant participating in the study is minimal. Only infants with stable breathing will be included and measuring an infant is short with two brief interruptions in CPAP treatment. Pauses and interruptions of CPAP is common during normal care, for example when the nasal interfaces are repositioned, nares cleaned or tubes replaced. The infant is not moved and there is no handling of the infant or tests performed. Routine monitoring will be in place. The study takes place in the neonatal intensive care ward where there is immediate access to equipment and staff experienced with life support if an infant is sick. In that case the measurement can be immediately stopped without problems for the infant or the study.

For an infant there are no advantages or disadvantages with participating in the study. If the measured FiO2 deviates and this will affect management, the staff will be notified. This could for example be decisions regarding surfactant or mechanical ventilation. This is a potential advantage for the individual patients.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• Vietnam
  • Hanoi, Vietnam, 118000
    • Phu San Hanoi Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study aims to include FiO2 measurements from bCPAP machines in use where the infants have stable spontaneous breathing and not expected to need urgent interventions.

Description

Inclusion Criteria:

• Admitted to Phu San Hanoi Hospital Neonatology Unit
• Bubble CPAP support with added O2
• ≥28 weeks GA
• Stable spontaneous breathing
• Investigation team available

Exclusion Criteria:

• Unstable infants in need of urgent intervention
• Major congenital malformation
• Known syndrome or neuromuscular disorder
• Circulatory instability with inotropes
• Recently extubated (<24 h)
• Recent large surgical procedure (<5 days)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Infant treated with bubble CPAP and receiving blended air/oxygen

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
FiO2 delivered	FiO2 in breathing circuit using an oxygen sensor	5 minutes
FiO2 estimated	FiO2 in breathing circuit estimated from flow meters by clinician	5 minutes

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	Any suspected or confirmed adverse events during and after recording of FiO2	up to one hour

Collaborators and Investigators

• Sponsor: Karolinska Institutet
• Collaborators: Göteborg University; Hanoi Medical University; Hanoi Obstetrics and Gynecology Hospital

Publications and helpful links

Helpful Links

• WHO guidelines including respiratory care

Study record dates

Study Major Dates

• Study Start (Actual): September 28, 2024
• Primary Completion (Actual): January 14, 2025
• Study Completion (Actual): February 1, 2025

Study Registration Dates

• First Submitted: September 24, 2024
• First Submitted That Met QC Criteria: September 24, 2024
• First Posted (Actual): September 26, 2024

Study Record Updates

• Last Update Posted (Estimated): May 20, 2025
• Last Update Submitted That Met QC Criteria: May 15, 2025
• Last Verified: September 1, 2024

More Information

Terms related to this study

• Keywords: Continuous Positive Airway Pressure; Respiratory Therapy
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Respiration Disorders; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Infant, Premature, Diseases; Infant, Newborn, Diseases
• Other Study ID Numbers: 2024-05506-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The datasets used and/or analysed during the current study will be available from the principal investigator on reasonable request after publication of results.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No